SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors HOPE-3 extension data showing slower upper-limb decline after patients switched to deramiocel is driving attention, with traders viewing it as supportive evidence ahead of the FDAs decision on the Duchenne treatment. The reaction is largely bullish, though some question how regulators will interpret the analyses and whether the data resolves earlier statistical concerns.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised FY2026 revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, is driving the sharp rally, alongside analyst upgrades. Traders are broadly bullish and speculate about short covering, while others flag profit-taking, overbought conditions, and possible dilution; upcoming cancer-trial data is also a source of optimism.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMPs sharp rally is fueling breakout chatter, with bulls pointing to its limited token supply, renewed DeFi interest, and speculation around the Clarity Act and incoming Fed chair Kevin Warsh. Others remain skeptical, calling the move speculative and noting COMPs weak performance relative to its past highs.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FICO is under pressure after FHFA changes put VantageScore alongside FICO in mortgage pricing, raising concerns that lenders could shift away from FICO and weaken its mortgage-scoring pricing power. Traders are divided between seeing a lasting threat to its competitive moat and viewing the selloff as an overreaction, with some pointing to continued lender use of FICO and buying the dip.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns fiscal Q4 earnings and forward outlook are dominating discussion, with traders focused on AI-driven HBM demand, tight DRAM and NAND supply, and how long strong pricing can last. Many expect a strong report, while others warn that high expectations and memorys cyclical history could prompt a sell-the-news reaction.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBAR is drawing attention for a sharp pullback after a strong rally, with traders debating whether it is a healthy correction or another pump-and-dump move amid concerns about sell pressure and the tokens large supply. Some dip buyers remain bullish, citing Hederas enterprise-AI narrative and reported IBM- and NVIDIA-related developments, while others question whether those themes justify the price action.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTDs slide to multiyear lows is being linked to slowing growth, weak advertising-spend expectations, and competition from Amazon and other automated ad platforms. Traders also debate an Apple/Safari ad-serving issue, while bears criticize management and some bullish posters point to the companys cash generation and see value after the selloff.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRX is drawing attention for its recent climb and repeated tests near $9, with traders debating whether the move reflects accumulation and potential short covering or another short-lived trading spike. The bullish case centers on anticipated ANKTIVA developmentsincluding a possible papillary bladder-cancer label expansion, upcoming trial data and international growthbut speculation about imminent news and a squeeze remains unconfirmed.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reported Lundbeck interest in acquiring Xeris has fueled takeover speculation and unusually heavy trading, although Xeris says it is not for sale and no deal is confirmed. Traders are debating whether the report signals a possible bid or is merely a rumor, while some see the companys pipeline as a reason to remain independent.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A federal judge paused the broader cannabis rescheduling case while considering whether to add a government report on DEA procedures to the record, delaying a potential Schedule III decision and weighing on cannabis ETFs. Traders disagree on whether the pause is a limited procedural delay or a setback that pushes the catalyst further out, with some viewing the selloff as a buying opportunity and others expressing frustration over the timeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


glenwoodnate

Nate Klingenstein